The Company’s oral abstract presentation features results from its clinical study that demonstrate the accuracy and medical application of its proprietary sensor.

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an oral abstract presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana on May 9, 2024 from 11:15 a.m. – 11:30 a.m. CDT.

The Company will present an abstract titled, “Efficacy of a Non-Invasive Blood Glucose Monitor for Diabetes Management Using a Radiofrequency Sensor and Machine Learning.” Know Labs first announced these interim results in March of this year from its clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting.

During 2024, as the Company continues on the path toward FDA clearance, Know Labs will deploy the KnowU™, its wearable, non-invasive continuous glucose monitor (CGM) in large-scale, external clinical trials while advancing model techniques and making refinements to the device. These new studies will help determine the technology’s performance throughout continuous wear, in more real-world environments, and within more extreme glycemic ranges (below 70 mg/dL and above 350 mg/dL). To stay updated on the latest results, visit www.knowlabs.co/research-and-development.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

For Know Labs Media Inquiries: Matter Health Abby Mayo Knowlabs@matternow.com Ph. (617) 272-0592 Know Labs, Inc. Contact: Jordyn Hujar jordyn@knowlabs.co Ph. (206) 629-6414

Grafico Azioni Know Labs (AMEX:KNW)
Storico
Da Ott 2024 a Nov 2024 Clicca qui per i Grafici di Know Labs
Grafico Azioni Know Labs (AMEX:KNW)
Storico
Da Nov 2023 a Nov 2024 Clicca qui per i Grafici di Know Labs